These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8955041)

  • 1. Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes.
    Jagodzinski PP; Wustner J; Kmieciak D; Wasik TJ; Fertala A; Sieron AL; Takahashi M; Tsuji T; Mimura T; Fung MS; Gorny MK; Kloczewiak M; Kaneko Y; Kozbor D
    Virology; 1996 Dec; 226(2):217-27. PubMed ID: 8955041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization.
    Zhang YJ; Fredriksson R; McKeating JA; Fenyö EM
    Virology; 1997 Nov; 238(2):254-64. PubMed ID: 9400598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1.
    Harrowe G; Cheng-Mayer C
    Virology; 1995 Jul; 210(2):490-4. PubMed ID: 7618285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of the inhibitory effect of curdlan sulfate on HIV-1 infection in vitro.
    Jagodzinski PP; Wiaderkiewicz R; Kurzawski G; Kloczewiak M; Nakashima H; Hyjek E; Yamamoto N; Uryu T; Kaneko Y; Posner MR
    Virology; 1994 Aug; 202(2):735-45. PubMed ID: 7913276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.
    Labrosse B; Treboute C; Brelot A; Alizon M
    J Virol; 2001 Jun; 75(12):5457-64. PubMed ID: 11356952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
    Delézay O; Hammache D; Fantini J; Yahi N
    Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
    Neurath AR; Strick N; Debnath AK
    J Mol Recognit; 1995; 8(6):345-57. PubMed ID: 9052975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection.
    Zanotto C; Calderazzo F; Dettin M; Di Bello C; Autiero M; Guardiola J; Chieco-Bianchi L; De Rossi A
    Virology; 1995 Feb; 206(2):807-16. PubMed ID: 7856094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120.
    Koito A; Stamatatos L; Cheng-Mayer C
    Virology; 1995 Feb; 206(2):878-84. PubMed ID: 7856100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.
    Nara P; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Krone W; Goudsmit J
    Dev Biol Stand; 1990; 72():315-41. PubMed ID: 2282990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
    Back NK; Smit L; De Jong JJ; Keulen W; Schutten M; Goudsmit J; Tersmette M
    Virology; 1994 Mar; 199(2):431-8. PubMed ID: 8122371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies.
    Mondor I; Moulard M; Ugolini S; Klasse PJ; Hoxie J; Amara A; Delaunay T; Wyatt R; Sodroski J; Sattentau QJ
    Virology; 1998 Sep; 248(2):394-405. PubMed ID: 9721247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.
    Yonezawa A; Hori T; Takaori-Kondo A; Morita R; Uchiyama T
    J Virol; 2001 May; 75(9):4258-67. PubMed ID: 11287575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein.
    Shimizu N; Haraguchi Y; Takeuchi Y; Soda Y; Kanbe K; Hoshino H
    Virology; 1999 Jul; 259(2):324-33. PubMed ID: 10388657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The V3 region of gp120 is responsible for anti-HIV-1 activity of heparin sulphate.
    Jagodzinski PP; Trzeciak WH
    Acta Biochim Pol; 1998; 45(3):799-804. PubMed ID: 9918507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.